Unified public procurement (UPA) and localisation incentives reshape a large import-dependent market. Sized from published research with a GCC and India lens, for buyers, suppliers and investors.
Unified public procurement (UPA) and localisation incentives reshape a large import-dependent market. Published estimates normalised to 2025 range from — to —; the Consulting Wallah central estimate is USD 1.8 bn, growing at about 7% a year to USD 2.9 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.
Growth is driven by population approaching 120 million with rising chronic disease (diabetes, CVD, cancer); universal Health Insurance rollout (law 2018; phased from Port Said to all 27 governorates over a decade); public health allocation EGP 397 bn (USD 7.8 bn) FY2023/24, +30% y/y; 23 new hospitals under construction.
Context that matters for buyers and suppliers: Egypt imports approximately 90% of its medical devices. EDA registration for Class II/III devices can take 12-24 months without prior preparation; local registration holder required. Egypt's pharma + medical supplies exports: USD 950 mn (2023), USD 1.07 bn (2024), USD 1.3 bn (2025), ~21% annual growth. EDA Central Administration for Medical Devices is simplifying registration with updated guidelines and templates.
The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is —–—; differences are mostly scope.
| Publisher (date) | Base value | Forecast | CAGR |
|---|---|---|---|
| Nexdigm (2026-04) — country / medical devices; blog gives forecast only, no base | None () | USD 3.5 bn ('by next decade') () | — |
| Market Research Future (2025-09 (updated 2026-09)) — labelled Egypt but page mixes MEA regional shares (GCC 12.5% | USD 28.59 bn (2025: USD 30.6 bn) (2024) | USD 56.4 bn (2035) | 6.37% (2025-2035) |
| US International Trade Administration (Country Commercial Guide) (2025-11) — country / public health budget, not device market size | EGP 397 bn (USD 7.8 bn) public health allocation FY2023/24 (+30% y/y) (2024) | — () | — |
| Egyptian Drug Authority (via Export Council for Medical Industries) (2026-05) — country / combined pharma + medical supplies exports, not ma | USD 1.3 bn exports of pharmaceuticals + medical supplies (2024: USD 1.07 bn; 2023: USD 0.95 bn) (2025) | — () | ~21% export growth |
| Consulting Wallah central estimate | USD 1.8 bn (2025) | USD 2.9 bn (2032) | ~7% |
Source: Publisher pages as listed under Sources; CW estimate as described in Method.
Included: capital equipment, implants, single-use consumables and IVD instruments and reagents. Excluded: pharmaceuticals, hospital IT, commodity PPE where reported separately. Publishers differ on whether IVD and consumables are included.
| Axis | Segment | Figure | Note |
|---|---|---|---|
| Application | Diagnostic devices | largest | |
| Application | Therapeutic devices | fastest-growing | |
| End use | Hospitals | largest | |
| End use | Home care | fastest-growing | |
| Device type | Electro-medical | largest | |
| Device type | Imaging | fastest-growing |
Source: As listed under Sources.
| Country / region | Figure | Year | Source |
|---|---|---|---|
| Egypt import dependence for medical devices | ~90% | 2026 | Taevas Global |
| Egypt total health expenditure | USD 20.71 bn (government share 37.2%) | 2021 | Market Research Future |
| Pharma + medical supplies exports to Africa | USD 324 mn (2024: USD 299 mn) | 2025 | EDA |
| New hospitals under construction | 23 (77% of projects nearing completion) | 2025 | US ITA |
Source: Sources as named; see Sources and method.
Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation
Opportunities we see: localisation push: EDA/Export Council roadmap to localise medical industries and raise exports (USD 1.3 bn pharma + supplies exports 2025, +21%); africa export hub ambitions (exports to Africa USD 324 mn in 2025); centralised UPA/UHIA tenders offering volume for pre-qualified suppliers.
| Date | Development | Source |
|---|---|---|
| 2026-05 | EDA joined Export Council for Medical Industries workshop on medical device exports and industry localisation; UPA represented | EDA |
| 2025-11 | US ITA updated Egypt Medical Equipment & Supplies commercial guide: 23 hospitals under construction, El Gomhoureya restructuring | US ITA |
| 2025-10 | Philips unveiled portable diagnostic devices for low-resource settings | Market Research Future |
| 2025-11 | Siemens Healthineers launched telehealth platform for remote patient monitoring | Market Research Future |
Source: Company and press announcements as named.
Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.
Published estimates normalised to 2025 range from — to —. Consulting Wallah’s central estimate is USD 1.8 bn in 2025, rising to about USD 2.9 bn by 2032.
See the sources listed on this page.
Siemens Healthineers, Medtronic, Philips, GE HealthCare, Johnson & Johnson, Baxter, Stryker, Boston Scientific among others.
The summary on this page is free to read and share with attribution. The full report is free for hospital leaders and registered Consulting Wallah Network members, and priced on request for others.
The full report (PDF, 40 pages) adds the GCC and India deep-dives, hospital-level benchmarks from the Consulting Wallah Network and the full source tables. Free for hospital leaders and registered network members; otherwise priced on request.
How to read these figures. Published market-size estimates for this market vary widely because publishers define scope differently (software only vs software + services + logistics). Where we show a Consulting Wallah estimate we state the range of published figures it is triangulated from and our scope. Figures marked as reported are quoted from the named source. Nothing here is investment advice.